Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
31 January 2014Website:
http://www.trevena.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 19 min agoDividend
Analysts recommendations
Institutional Ownership
TRVN Latest News
CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.
Shares of Trevena Inc. TRVN exploded more than five-fold higher — up 420.6% — on very active trading Monday, after the Pennsylvania-based biopharmaceutical company said its China-based partner Jiangsu Nhwa received formal approval from China health regulators for the pain treatment Olinvyk. The stock, which had been halted 21 times for volatility since the open, has seen 75.7 million shares change hands, compared with the full-day average over the past 30 days of about 111,100 shares.
Trevena (NASDAQ: TRVN ) stock is rocketing higher on Monday after Chinese partner Jiangsu Nhwa got approval for one of its treatments. The National Medical Products Administration granted approval to Jiangsu Nhwa for Trevena's OLINVYK.
Trevena, Inc. (NASDAQ:TRVN ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities Brandon Folkes - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call.
What type of business is Trevena?
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
What sector is Trevena in?
Trevena is in the Healthcare sector
What industry is Trevena in?
Trevena is in the Biotechnology industry
What country is Trevena from?
Trevena is headquartered in United States
When did Trevena go public?
Trevena initial public offering (IPO) was on 31 January 2014
What is Trevena website?
https://www.trevena.com
Is Trevena in the S&P 500?
No, Trevena is not included in the S&P 500 index
Is Trevena in the NASDAQ 100?
No, Trevena is not included in the NASDAQ 100 index
Is Trevena in the Dow Jones?
No, Trevena is not included in the Dow Jones index
When does Trevena report earnings?
The next expected earnings date for Trevena is 14 August 2024